The U.S. Food and Drug Administration (FDA) has listed NDA215007 for a carbon dioxide inhalation product. The product is branded as Carbon Dioxide, USP and is classified as a human prescription drug.
It is administered by respiratory inhalation in a gas dosage form and is marketed as a prescription product. The FDA record includes multiple package NDC codes (e.g., 12213-900-11, 12213-900-12, 12213-900-13, etc.) associated with the product.
NexAir, LLC is identified as the sponsor and manufacturer of the product.
The original submission (type ORIG) was filed with a letter dated July 31, 2020. The submission status is recorded as AP (approved) with a status date of July 18, 2020.
Regulatory UpdatesSep 18, 2026•3 min read
FDA Approves NexAir’s Prescription Carbon Dioxide Inhalation Product (NDA215007)
The FDA’s NDA215007 for NexAir’s carbon dioxide inhalation gas (USP) is listed with approval status AP, detailing route, dosage form, and NDC codes.
Compiled by the Pharmacountry team · Source: FDA.gov
Topics:
Ratings
(0)
(0)
(0)
(0)
(0)
Leave your rating